Upstream Bio, Inc. (UPB) shareholders
Close on Nov 17, 2026Market cap $115.02MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (14.80%) | 7,936,880 | 14.80% | 13G (passive) amendment | Jun 30, 2025 |
| Len Blavatnik Joint filing with AI Upstream LLC (10.70%), Access Industries Holdings LLC (10.70%) and 2 more | 5,494,410 | 10.70% | 13D (active) | Oct 15, 2024 |
| OrbiMed Capital GP VIII LLC Joint filing with OrbiMed Advisors LLC (8.90%) | 4,554,873 | 8.90% | 13D (active) | Oct 15, 2024 |
| Norges Bank | 4,206,586 | 7.73% | 13G (passive) amendment | Jun 30, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (6.90%) | 3,793,955 | 6.90% | 13G (passive) amendment | Oct 30, 2026 |
| Xiangmin Cui Joint filing with Decheng Capital Global Life Sciences Fund IV, L.P. (5.80%), Decheng Capital Management IV (Cayman), LLC (5.80%) | 3,285,293 | 6.10% | 13G (passive) | Dec 31, 2024 |
| BlackRock, Inc. | 2,814,714 | 5.20% | 13G (passive) | Jun 30, 2026 |
| TCG Crossover Fund I, L.P. Joint filing with TCG Crossover GP I, LLC (5.20%), Chen Yu (5.20%) | 2,801,763 | 5.20% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of UPB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 8,162,897 | 14.90% | $56.49M | +61,334 | 0.00% |
| Orbimed Advisors LLC | 5,693,589 | 10.40% | $39.40M | – | 0.73% |
| Norges Bank | 3,768,619 | 6.88% | $26.08M | New | 0.00% |
| BlackRock, Inc. | 3,753,358 | 6.85% | $25.97M | +382,669 | 0.00% |
| Decheng Capital LLC | 2,724,868 | 4.98% | $18.86M | – | 2.58% |
| Enavate Sciences Gp, LLC | 2,459,703 | 4.49% | $17.02M | – | 4.93% |
| Vanguard Capital Management LLC | 1,876,734 | 3.43% | $12.99M | +3,160 | 0.00% |
| Millennium Management LLC | 1,143,775 | 2.09% | $7.91M | +206,452 | 0.00% |
| D. E. Shaw & Co., Inc. | 1,036,044 | 1.89% | $7.17M | +215,564 | 0.00% |
| JPMorgan Chase & Co | 1,012,044 | 1.85% | $7.01M | +549,043 | 0.00% |
| Qube Research & Technologies Ltd | 978,500 | 1.79% | $6.77M | +359,179 | 0.01% |
| Parkman Healthcare Partners LLC | 935,247 | 1.71% | $6.47M | +148,464 | 0.66% |
| Geode Capital Management, LLC | 931,261 | 1.70% | $6.45M | −19,356 | 0.00% |
| SEB Asset Management AB | 878,473 | 1.60% | $6.08M | – | 0.02% |
| Woodline Partners LP | 831,481 | 1.52% | $5.75M | – | 0.02% |
| State Street Corp | 766,323 | 1.40% | $5.30M | +60,973 | 0.00% |
| Vanguard Portfolio Management LLC | 712,667 | 1.30% | $4.93M | −15,044 | 0.00% |
| Y-Intercept (Hong Kong) Ltd | 693,555 | 1.27% | $4.80M | −307,076 | 0.09% |
| Bain Capital Life Sciences Investors, LLC | 600,949 | 1.10% | $4.16M | −266,262 | 0.25% |
| Aqr Capital Management LLC | 544,869 | 0.99% | $3.77M | +472,698 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 149 | 51M | 92.3% | 38 / 65 | 28 / 28 | 11M | 5M |
| Q1 2026 | 140 | 45M | 82.0% | 47 / 47 | 35 / 38 | 13M | 17M |
| Q4 2025 | 133 | 51M | 93.4% | 46 / 42 | 33 / 8 | 12M | 5M |
| Q3 2025 | 95 | 44M | 81.2% | 22 / 38 | 22 / 10 | 4M | 8M |
| Q2 2025 | 83 | 48M | 88.3% | 14 / 41 | 13 / 10 | 5M | 3M |
| Q1 2025 | 79 | 46M | 84.5% | 24 / 11 | 26 / 14 | 6M | 1M |
| Q4 2024 | 70 | 42M | 76.8% | 70 / 0 | 0 / 0 | 42M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
147 funds held UPB in Q2 2026, 30% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of UPB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,443,025 | 2.63% | $9.99M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 1,371,372 | 2.50% | $8.65M | 0.10% | Jul 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 1,321,800 | 2.41% | $8.34M | 0.11% | Jul 31, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 965,800 | 1.76% | $6.09M | 0.13% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 921,063 | 1.68% | $6.37M | 0.01% | Jun 30, 2026 |
| Select Health Care Portfolio | 800,000 | 1.46% | $6.69M | 0.12% | May 31, 2026 |
| Fidelity Small Cap Growth K6 Fund | 693,618 | 1.27% | $4.38M | 0.10% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 691,003 | 1.26% | $4.36M | 0.20% | Jul 31, 2026 |
| Fidelity Advisor Health Care Fund | 400,000 | 0.73% | $2.52M | 0.08% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 386,877 | 0.71% | $2.68M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 384,509 | 0.70% | $2.43M | 0.01% | Jul 31, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 341,675 | 0.62% | $2.86M | 0.05% | May 29, 2026 |
| iShares Russell 2000 Value ETF | 338,261 | 0.62% | $2.34M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF | 256,130 | 0.47% | $1.77M | 0.02% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 234,657 | 0.43% | $1.96M | 0.04% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Everett Rand Sutherland | Chief Executive Officer, Director | 68,717 | 0.13% | Sep 17, 2026 |
| Aaron Deykin | Chief Medical Officer | 32,302 | 0.06% | Sep 17, 2026 |
| Allison Ambrose | General Counsel | 15,563 | 0.03% | Sep 17, 2026 |
| Michael Gray | CFO and COO | 27,942 | 0.05% | Sep 17, 2026 |
| Adam Houghton | Chief Business Officer | 22,901 | 0.04% | Sep 17, 2026 |
| Erez Chimovits | Director | 4,554,873 | 8.32% | Jun 11, 2026 |
| Harold Edward Fleming | Director | – | – | Jun 11, 2026 |
| Liam Ratcliffe | Director | – | – | Jun 11, 2026 |
| Marcella K. Ruddy | Director | – | – | Jun 11, 2026 |
| Ronald C. Renaud JR | Director | – | – | Jun 11, 2026 |
| Daniella Beckman | Director | – | – | Jun 11, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Adam Houghton Chief Business Officer | Sep 16, 2026 | Sale | −700 | $5.49 | $3.84K | 22,901 |
| Michael Gray CFO and COO | Sep 16, 2026 | Sale | −853 | $5.49 | $4.68K | 27,942 |
| Allison Ambrose General Counsel | Sep 16, 2026 | Sale | −485 | $5.49 | $2.66K | 15,563 |
| Aaron Deykin Chief Medical Officer | Sep 16, 2026 | Sale | −895 | $5.49 | $4.91K | 32,302 |
| Everett Rand Sutherland Chief Executive Officer, Director | Sep 16, 2026 | Sale | −2,095 | $5.49 | $11.50K | 68,717 |
| Michael Gray CFO and COO | Jun 16, 2026 | Sale | −853 | $6.10 | $5.20K | 28,795 |
| Aaron Deykin Chief Medical Officer | Jun 16, 2026 | Sale | −895 | $6.10 | $5.46K | 33,197 |
| Allison Ambrose General Counsel | Jun 16, 2026 | Sale | −477 | $6.10 | $2.91K | 16,048 |
| Adam Houghton Chief Business Officer | Jun 16, 2026 | Sale | −700 | $6.10 | $4.27K | 23,601 |
| Everett Rand Sutherland Chief Executive Officer, Director | Jun 16, 2026 | Sale | −2,095 | $6.10 | $12.78K | 70,812 |
| Everett Rand Sutherland Chief Executive Officer, Director | Mar 16, 2026 | Sale | −2,093 | $9.29 | $19.44K | 72,907 |
| Aaron Deykin Chief Medical Officer | Mar 16, 2026 | Sale | −894 | $9.29 | $8.31K | 32,687 |
| Michael Gray CFO and COO | Mar 16, 2026 | Sale | −852 | $9.29 | $7.92K | 29,648 |
| Adam Houghton Chief Business Officer | Mar 16, 2026 | Sale | −699 | $9.29 | $6.49K | 24,301 |
| Allison Ambrose General Counsel | Mar 16, 2026 | Sale | −475 | $9.29 | $4.41K | 16,525 |
| Everett Rand Sutherland Chief Executive Officer, Director | Jan 2, 2026 | Award | +75,000 | – | – | 75,000 |
| Allison Ambrose General Counsel | Jan 2, 2026 | Award | +17,000 | – | – | 17,000 |
| Adam Houghton Chief Business Officer | Jan 2, 2026 | Award | +25,000 | – | – | 25,000 |
| Michael Gray CFO and COO | Jan 2, 2026 | Award | +30,500 | – | – | 30,500 |
| Aaron Deykin Chief Medical Officer | Jan 2, 2026 | Award | +32,000 | – | – | 33,581 |
| Erez Chimovits Director, 10% owner | Oct 15, 2024 | Buy | +660,000 | $17.00 | $11.22M | 4,554,873 |
| Erez Chimovits Director, 10% owner | Oct 15, 2024 | Conversion | +2,887,833 | – | – | 3,894,873 |
| Erez Chimovits Director, 10% owner | Oct 15, 2024 | Buy | +165,000 | $17.00 | $2.81M | 1,138,716 |
| Erez Chimovits Director, 10% owner | Oct 15, 2024 | Conversion | +721,956 | – | – | 973,716 |
| Industries Holdings LLC Access 10% owner | Oct 15, 2024 | Conversion | +1,172,410 | – | – | 5,494,410 |
| Industries Holdings LLC Access 10% owner | Oct 15, 2024 | Conversion | +3,147,000 | – | – | 4,322,000 |
| Industries Holdings LLC Access 10% owner | Oct 15, 2024 | Buy | +1,175,000 | $17.00 | $19.98M | 1,175,000 |
| Advisors Llc Orbimed Director, 10% owner | Oct 15, 2024 | Buy | +660,000 | $17.00 | $11.22M | 4,554,873 |
| Advisors Llc Orbimed Director, 10% owner | Oct 15, 2024 | Conversion | +721,956 | – | – | 973,716 |
| Advisors Llc Orbimed Director, 10% owner | Oct 15, 2024 | Buy | +165,000 | $17.00 | $2.81M | 1,138,716 |
| Advisors Llc Orbimed Director, 10% owner | Oct 15, 2024 | Conversion | +2,887,833 | – | – | 3,894,873 |
| Biomedical Innovation Master Investors (Cayman) II L.P. Wellington 10% owner | Oct 15, 2024 | Conversion | +894,733 | – | – | 894,733 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Upstream Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 10,112 shares on Oct 5, 2026 over the last 90 days.
See a number that looks wrong?